Please login to the form below

Not currently logged in
Email:
Password:

adalimumab-atto

This page shows the latest adalimumab-atto news and features for those working in and with pharma, biotech and healthcare.

New EU and US approvals for Humira biosimilars

New EU and US approvals for Humira biosimilars

Humira (adalimumab) has been the wold's biggest selling drug for years, and made $16bn in sales last year for AbbVie, with a little under $6bn of that total coming from ... It is the second to claim marketing approval in the US market after Amgen's

Latest news

  • Amgen wins European approval for Humira biosimilar Amgevita Amgen wins European approval for Humira biosimilar Amgevita

    Amgevita (biosimilar adalimumab) is both Amgen’s first biosimilar and now the first Humira biosimilar to be approved in Europe. ... Amgen’s Humira biosimilar was approved last September in the US under the brand name Amjevita (adalimumab-atto), whose

  • Amgen claims first US go-ahead for Humira biosimilar Amgen claims first US go-ahead for Humira biosimilar

    brand. The approval is however just the first step in what is likely to be a long journey before the biosimilar - called Amjevita (adalimumab-atto; formerly ABP 501) - can be prescribed ... Meanwhile AbbVie has already filed a lawsuit against Amgen

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics